Ignite Creation Date:
2025-12-24 @ 4:12 PM
Ignite Modification Date:
2025-12-27 @ 9:40 PM
Study NCT ID:
NCT05024266
Status:
UNKNOWN
Last Update Posted:
2021-08-27
First Post:
2021-08-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma
Sponsor:
First Affiliated Hospital of Zhejiang University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-08-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-08-31
Completion Date Type:
ESTIMATED
First Submit Date:
2021-08-10
First Submit QC Date:
None
Study First Post Date:
2021-08-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-08-22
Last Update Post Date:
2021-08-27
Last Update Post Date Type:
ACTUAL